Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation

Preliminary responses observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumab Early antitumor activity also observed in squamous NSCLC, SCLC and prostate cancer SHANGHAI and HANGZHOU, China, Oct. 29,...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.